• Medical_Professionals
• Medical_students
• Nurses

Urologists and those practicing urology need a thorough knowledge of the most recent developments and techniques in urology to ensure the highest standards of patient care and safety. This program is designed to inform on the technical aspects of the surgical management and treatment of urologic cancer, focusing on the diagnosis, treatment, clinical advances, and controversies in localized and advanced urologic cancers; stress urinary incontinence (SUI); management and treatment of urolithiasis; urethral stricture disease; and benign hyperplasia.

Learning Objectives
After completion of this course, attendees should be able to:

• Define evidence-based outcomes of thermal ablative procedures for benign prostatic hyperplasia.
• Identify technological advances that facilitate the endoscopic management of transitional cell cancer.
• Identify ten surgical tips for flexible ureteroscopy to optimize outcomes and minimize complications. Detail the surgical steps for endoscopic-guided percutaneous renal access for stone extraction.
• Describe instrumentation required for single-port laparoscopic and robotic procedures.
• Identify treatment strategies to optimize outcomes and minimize complications with extracorporeal shockwave lithotripsy. Detail evidence-based guidelines for medical and dietary kidney stone prevention.
• Define the diagnostic and therapeutic algorithms for management of the patient with blunt and penetrating urologic trauma.
• Outline the diagnostic trouble-shooting and management steps for the patient with a malfunctioning artificial urinary sphincter . Stratify patient management for urethral strictures.
• Identify patients with advanced bladder cancer who are candidates for neoadjuvant or adjuvant chemotherapy.
• Detail the selection criteria for specific urinary diversions, and the long-term outcomes associated with each approach.
• Discuss the management of the patient with carcinoma-in-situ of the bladder. Define appropriate selection of autologous, allograft and synthetic sling materials.
• Detail the alternatives for medical therapy of advanced renal cell cancer and prostate cancer.
• Identify key surgical steps in robotic partial nephrectomy.
• Detail evidence-based guidelines for the management of small renal masses.
• Define differences in technology and outcomes for thermo-ablative approaches to renal cell cancer.
• Identify effective strategies to decrease the risk of post-prostatectomy incontinence.
• Detail the application of genomics to the risk stratification of the prostate cancer patient.

USD

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

Sheraton Waikiki
2255 Kalakaua Avenue
Honololu, Hawaii, 96815
Phone: 808-922-4422
Fax: 808-931-8883

The Sheraton Waikiki is a modern monument to traditional Hawaiian hospitality. This fabulous oceanfront hotel offers inspiring views of the Ko'olau Mountains and Waikiki surf during the day and sparkling city lights of Honolulu in the evening. The Sheraton Waikiki is your gateway to Hawaii's favorite playground, Waikiki Beach.

Book your reservation online or call 808-921-4611.

Submission Info

Online Abstract Submission Process Begins: July 31, 2014

Abstract Deadline Date: January 9, 2015 at 11 p.m. EST

Submitted abstracts are graded individually by peer reviewers based on scientific merit and originality. Abstracts must be written in English.

Multiple abstracts by the same authors based on the same study population or data will be rejected outright.

Preparation of Abstracts

1. Size: The size of the abstract is limited to 300 words or 2,280 characters not including spaces. This includes title, body of abstract, tables and graphics.
2. Title: The title should clearly define the topic and contain no abbreviations.
3. Authors: List the primary author's full name, followed by the other authors' names. Spell out completely the names of all authors using full first name, middle initial and last name.
4. Body of Abstract: The abstract should be informative and detailed.
• The body must contain 4 separate paragraphs:
1. Introduction and Objective
2. Methods
3. Results
4. Conclusions
• It is NOT acceptable to state that "The results will be discussed." Inclusion of specific data is helpful to the reviewers.
• Indicate the major new findings of the study.
• Standard abbreviations may be used as follows: on first use spell out the full term and follow with the abbreviation in parentheses.
• Graphs and/or tables may be used; characters in graphs and tables are counted towards the overall character limit of the abstract.
• Proprietary names of drugs are not allowed; generic names must be used.
• Source of Funding: Grant support must be indicated on the "Source of Funding" page. If there is no support, "None" must be listed. This is a required field in the submission process. Abstracts deemed to be purely for marketing purposes will not be accepted.
• Conflict of Interest and Disclosure Statement: All authors must disclose conflicts of interest.

American Urological Association
444 N. Capitol Street, NW, Suite 414
Washington, D.C. 20001
Phone: 202-403-8500
Fax: 202-403-8506

General Inquiries
Phone: 410-689-3700
Email: aua@AUAnet.org

American Urological Association
444 N. Capitol Street, NW, Suite 414
Washington, D.C. 20001
Phone: 202-403-8500
Fax: 202-403-8506

General Inquiries
Phone: 410-689-3700
Email: aua@AUAnet.org